# P3 Health Partners Inc.: financial statements, quarterly

PIII · Nasdaq · CIK 1832511 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/piii.md) · [Financials](/companies/piii/financials.md) · [Filings](/companies/piii/filings.md) · [Insiders](/companies/piii/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/piii/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [288](/filings/0001628280-24-047186.md) | [347 d](/filings/0001628280-25-015305.md) | [388](/filings/0001628280-25-026021.md) | [379](/filings/0001832511-25-000013.md) | [362](/filings/0001832511-25-000025.md) | [371 d](/filings/0001832511-26-000011.md) | [373](/filings/0001832511-26-000022.md) | [356](/filings/0001832511-26-000034.md) | [345](/filings/0001832511-25-000025.md) | [385 d](/filings/0001832511-26-000011.md) | [386](/filings/0001832511-26-000022.md) | [386](/filings/0001832511-26-000034.md) |
| Operating income | $m | [(33.8)](/filings/0001628280-24-047186.md) | [(64.3) d](/filings/0001628280-25-015305.md) | [(43.8)](/filings/0001628280-25-026021.md) | [(31.3)](/filings/0001832511-25-000013.md) | [(107)](/filings/0001832511-25-000025.md) | [(139) d](/filings/0001832511-26-000011.md) | [(38.1)](/filings/0001832511-26-000022.md) | [(34.1)](/filings/0001832511-26-000034.md) | [(44.2)](/filings/0001832511-25-000025.md) | [(154) d](/filings/0001832511-26-000011.md) | [8.2](/filings/0001832511-26-000022.md) | [41.2](/filings/0001832511-26-000034.md) |
| Income tax | $m | [0.4](/filings/0001628280-24-047186.md) | [1.8 d](/filings/0001628280-25-015305.md) | [2.1](/filings/0001628280-25-026021.md) | [1.0](/filings/0001832511-25-000013.md) | [(3.6)](/filings/0001832511-25-000025.md) | [5.0 d](/filings/0001832511-26-000011.md) | [1.1](/filings/0001832511-26-000022.md) | [2.0](/filings/0001832511-26-000034.md) | [0.0](/filings/0001832511-25-000025.md) | [(1.0) d](/filings/0001832511-26-000011.md) | [(11.0)](/filings/0001832511-26-000022.md) | [1.3](/filings/0001832511-26-000034.md) |
| Net income | $m | [(13.3)](/filings/0001628280-24-047186.md) | [(25.5) d](/filings/0001628280-25-015305.md) | [(18.7)](/filings/0001628280-25-026021.md) | [(12.0)](/filings/0001832511-25-000013.md) | [(46.5)](/filings/0001832511-25-000025.md) | [(58.6) d](/filings/0001832511-26-000011.md) | [(20.5)](/filings/0001832511-26-000022.md) | [(20.4)](/filings/0001832511-26-000034.md) | [(31.6)](/filings/0001832511-25-000025.md) | [(75.5) d](/filings/0001832511-26-000011.md) | [1.2](/filings/0001832511-26-000022.md) | [7.4](/filings/0001832511-26-000034.md) |
| Diluted EPS | $ per share | [(0.12)](/filings/0001628280-24-047186.md) | not reported | [(7.86)](/filings/0001628280-25-026021.md) | [(7.37)](/filings/0001832511-25-000013.md) | [(15.70)](/filings/0001832511-25-000025.md) | not reported | [(6.28)](/filings/0001832511-26-000022.md) | [(6.23)](/filings/0001832511-26-000034.md) | [(9.67)](/filings/0001832511-25-000025.md) | not reported | [0.32](/filings/0001832511-26-000022.md) | [(0.63)](/filings/0001832511-26-000034.md) |
| Basic EPS | $ per share | [(0.12)](/filings/0001628280-24-047186.md) | not reported | [(7.86)](/filings/0001628280-25-026021.md) | [(4.40)](/filings/0001832511-25-000013.md) | [(14.36)](/filings/0001832511-25-000025.md) | not reported | [(6.28)](/filings/0001832511-26-000022.md) | [(6.23)](/filings/0001832511-26-000034.md) | [(9.67)](/filings/0001832511-25-000025.md) | not reported | [0.37](/filings/0001832511-26-000022.md) | [(0.63)](/filings/0001832511-26-000034.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [52.6](/filings/0001628280-23-037821.md) | [36.3](/filings/0001628280-25-015305.md) | [27.3](/filings/0001628280-24-021690.md) | [73.1](/filings/0001628280-24-035649.md) | [63.0](/filings/0001832511-25-000025.md) | [38.8](/filings/0001832511-26-000011.md) | [40.1](/filings/0001832511-26-000022.md) | [38.6](/filings/0001832511-26-000034.md) | [37.7](/filings/0001832511-25-000025.md) | [25.0](/filings/0001832511-26-000034.md) | [25.5](/filings/0001832511-26-000022.md) | [21.3](/filings/0001832511-26-000034.md) |
| Current assets | $m | [180](/filings/0001628280-23-037821.md) | [166](/filings/0001628280-25-015305.md) | [183](/filings/0001628280-24-021690.md) | [242](/filings/0001628280-24-035649.md) | [215](/filings/0001628280-24-047186.md) | [184](/filings/0001832511-26-000011.md) | [191](/filings/0001628280-25-026021.md) | [157](/filings/0001832511-25-000013.md) | [136](/filings/0001832511-25-000025.md) | [133](/filings/0001832511-26-000034.md) | [172](/filings/0001832511-26-000022.md) | [179](/filings/0001832511-26-000034.md) |
| Total assets | $m | [897](/filings/0001628280-23-037821.md) | [861](/filings/0001628280-25-015305.md) | [856](/filings/0001628280-24-021690.md) | [893](/filings/0001628280-24-035649.md) | [833](/filings/0001628280-24-047186.md) | [783](/filings/0001832511-26-000011.md) | [784](/filings/0001628280-25-026021.md) | [732](/filings/0001832511-25-000013.md) | [684](/filings/0001832511-25-000025.md) | [657](/filings/0001832511-26-000034.md) | [674](/filings/0001832511-26-000022.md) | [654](/filings/0001832511-26-000034.md) |
| Current liabilities | $m | [267](/filings/0001628280-23-037821.md) | [299](/filings/0001628280-25-015305.md) | [334](/filings/0001628280-24-021690.md) | [352](/filings/0001628280-24-035649.md) | [405](/filings/0001628280-24-047186.md) | [496](/filings/0001832511-26-000011.md) | [507](/filings/0001628280-25-026021.md) | [505](/filings/0001832511-25-000013.md) | [424](/filings/0001832511-25-000025.md) | [545](/filings/0001832511-26-000034.md) | [525](/filings/0001832511-26-000022.md) | [389](/filings/0001832511-26-000034.md) |
| Total liabilities | $m | [396](/filings/0001628280-23-037821.md) | [427](/filings/0001628280-25-015305.md) | [470](/filings/0001628280-24-021690.md) | [528](/filings/0001628280-24-035649.md) | [569](/filings/0001628280-24-047186.md) | [634](/filings/0001832511-26-000011.md) | [663](/filings/0001628280-25-026021.md) | [644](/filings/0001832511-25-000013.md) | [665](/filings/0001832511-25-000025.md) | [797](/filings/0001832511-26-000034.md) | [807](/filings/0001832511-26-000022.md) | [517](/filings/0001832511-26-000034.md) |
| Long-term debt | $m | [108](/filings/0001628280-23-037821.md) | [108](/filings/0001628280-25-015305.md) | [118](/filings/0001628280-24-021690.md) | [133](/filings/0001628280-24-035649.md) | [133](/filings/0001628280-24-047186.md) | [109](/filings/0001832511-26-000011.md) | [106](/filings/0001628280-25-026021.md) | [102](/filings/0001832511-25-000013.md) | [214](/filings/0001832511-25-000025.md) | [228](/filings/0001832511-26-000034.md) | [260](/filings/0001832511-26-000022.md) | [98.1](/filings/0001832511-26-000034.md) |
| Current portion of debt | $m | [0.0](/filings/0001628280-23-037821.md) | [0.0](/filings/0001628280-25-015305.md) | not reported | not reported | not reported | [75.2](/filings/0001832511-26-000011.md) | [65.0](/filings/0001628280-25-026021.md) | [80.0](/filings/0001832511-25-000013.md) | [38.6](/filings/0001832511-25-000025.md) | [45.0](/filings/0001832511-26-000034.md) | [51.4](/filings/0001832511-26-000022.md) | [21.8](/filings/0001832511-26-000034.md) |
| Short-term borrowings | $m | not reported | [0.0](/filings/0001628280-24-047186.md) | [1.4](/filings/0001628280-24-021690.md) | [0.8](/filings/0001628280-24-035649.md) | [0.2](/filings/0001628280-24-047186.md) | [0.0](/filings/0001832511-25-000025.md) | [0.8](/filings/0001628280-25-026021.md) | [0.5](/filings/0001832511-25-000013.md) | [0.1](/filings/0001832511-25-000025.md) | [0.0](/filings/0001832511-26-000034.md) | [0.8](/filings/0001832511-26-000022.md) | [0.4](/filings/0001832511-26-000034.md) |
| Shareholders' equity | $m | [188](/filings/0001628280-24-047186.md) | [142](/filings/0001832511-26-000011.md) | [147](/filings/0001832511-25-000025.md) | [167](/filings/0001832511-25-000025.md) | [121](/filings/0001832511-25-000025.md) | [75.9](/filings/0001832511-26-000011.md) | [63.3](/filings/0001832511-25-000025.md) | [44.5](/filings/0001832511-26-000034.md) | [(18.7)](/filings/0001832511-25-000025.md) | [(155)](/filings/0001832511-26-000011.md) | [(144)](/filings/0001832511-26-000034.md) | [73.2](/filings/0001832511-26-000034.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(7.6) d](/filings/0001628280-24-047186.md) | [(15.9) d](/filings/0001628280-25-015305.md) | [(20.0)](/filings/0001628280-25-026021.md) | [(10.2) d](/filings/0001832511-25-000013.md) | [(22.6) d](/filings/0001832511-25-000025.md) | [(57.2) d](/filings/0001832511-26-000011.md) | [(33.5)](/filings/0001832511-26-000022.md) | [(16.6) d](/filings/0001832511-26-000034.md) | [(15.4) d](/filings/0001832511-25-000025.md) | [(25.7) d](/filings/0001832511-26-000011.md) | [(27.5)](/filings/0001832511-26-000022.md) | [(61.9) d](/filings/0001832511-26-000034.md) |
| Capital expenditure | $m | [0.4 d](/filings/0001628280-24-047186.md) | [(0.2) d](/filings/0001628280-25-015305.md) | [0.0](/filings/0001628280-24-021690.md) | [0.0 d](/filings/0001628280-24-035649.md) | [0.0 d](/filings/0001832511-25-000025.md) | [0.0 d](/filings/0001628280-25-015305.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [243](/filings/0001628280-23-037821.md) | [41.6](/filings/0001628280-24-021690.md) | [107](/filings/0001628280-24-035649.md) | [313](/filings/0001628280-24-047186.md) | [2.4](/filings/0001628280-25-026021.md) | [2.8](/filings/0001832511-25-000013.md) | [3.3](/filings/0001832511-25-000025.md) | [3.3](/filings/0001832511-26-000022.md) | [3.3](/filings/0001832511-26-000034.md) | [3.3](/filings/0001832511-25-000025.md) | [8.4](/filings/0001832511-26-000022.md) | [3.4](/filings/0001832511-26-000034.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.